Oral sulfate-based versus low-volume polyethylene glycol-ascorbate regimens for colonoscopy preparation in the geriatric population: a systematic review and meta-analysis of randomized controlled trials Authors: Ali Emre Bardak, Gizem Teker, Yusuf Yalcin, Stefan Mitev, Ayse Ipek Bardak, Zulal Istemihan, Nazli Begum Ozturk, Sandeep Krishnan Published: 2026 ABSTRACT AbstractBackground/AimsAdequate bowel preparation is essential for high-quality colonoscopy; however, older adults often struggle with large-volume regimens. Low-volume oral sulfate (OS)-based and polyethylene glycol-ascorbate (PEG-Asc) may improve tolerability without compromising efficacy. This study compared the efficacy, tolerability, and safety of these regimens in older adults.MethodsWe searched the PubMed, Embase, and Cochrane databases from inception until May 2025 for randomized controlled trials comparing OS with low-volume PEG-Asc in adults aged ≥65 years. Outcomes were pooled using random-effects models as risk ratios (RRs) or mean differences (MDs).ResultsSix trials (n=682; OS, 340; PEG-Asc, 342) were included. The overall cleansing success rates were comparable (RR, 1.00; 95% confidence interval [CI], 0.96–1.03). Total Boston bowel preparation scale and segmental scores did not significantly differ between the groups (MD, 0.08; 95% CI, −0.10 to 0.27). OS improved lesion detection in terms of polyp detection (RR, 1.21; 95% CI, 1.01–1.45) and adenoma detection rates (RR, 1.28; 95% CI, 1.10–1.49). Patient-reported satisfaction modestly favored OS compared with PEG-Asc (MD, 0.69; 95% CI, 0.10–1.29), whereas willingness to reuse was similar between the two groups (RR, 1.09; 95% CI, 0.97–1.23). Adverse events and procedural metrics did not significantly differ between the groups.ConclusionsIn adults aged ≥65 years, OS and low-volume PEG-Asc achieved similar cleansing quality and safety. OS may confer higher polyp and adenoma detection rates than PEG-Asc and may be a reasonable option for maximizing lesion detection.Keywords: Adenoma, Aged, Colonoscopy, Polyethylene glycols, Sulfates Graphical abstract INTRODUCTION Colonoscopy is the gold standard for colorectal cancer (CRC) screening and is utilized in the diagnosis and treatment of various colorectal diseases.1 Colonoscopic procedures are rapidly advancing to improve diagnostic accuracy and expand therapeutic capabilities.2 However, the quality of bowel preparation remains a key determinant of procedural success.3 Inadequate bowel cleansing may increase procedural risks, lead to poorer diagnostic and therapeutic yields, necessitate repeat procedures, increase healthcare costs, and ultimately worsen health-related outcomes.3-5 Therefore, ensuring effective bowel preparation is essential. The efficacy of bowel preparation regimens plays a crucial role in successful bowel preparation. However, patient compliance and tolerability are equally important. The main factors affecting compliance and tolerability include the volume and palatability of the preparation solution, as well as gastrointestinal side effects such as nausea, vomiting, and abdominal pain.3,4 To optimize these factors, lower-volume, more palatable preparations with fewer side effects are under investigation. Thus, the addition of ascorbic acid as an adjunct to low-volume (≤2 L) polyethylene glycol (PEG) solutions has allowed them to achieve comparable efficacy to high-volume (4 L) PEG solutions, while also providing improved compliance and tolerability.3,6,7 Similarly, oral sulfate (OS)-based regimens, including oral sulfate solutions (OSS) and oral sulfate tablets (OST), have emerged as effective low-volume alternatives.8,9 Age ≥65 years is an independent risk factor for inadequate bowel preparation owing to a combination of age-related physiological changes and higher prevalence of comorbid conditions, including slowed gastrointestinal motility, reduced mobilization, reduced tolerance of large fluid volumes, and cognitive impairment.10-13 As such, bowel preparation in older patients requires special attention. Low-volume polyethylene glycol-ascorbate (PEG-Asc) and OS regimens are two low-volume bowel preparation regimens that have been widely adopted with the endorsement of major gastroenterology societies; however, evidence in the geriatric population is fragmented and often embedded in mixed-age trials.3,14,15 In this meta-analysis, we aimed to compare their use in the geriatric population (age ≥65 years) in terms of efficacy and tolerability. METHODS This systematic review and meta-analysis was designed and conducted in line with the Cochrane Collaboration Handbook for Systematic Reviews of Interventions.16 Reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.17 The protocol was registered in the International Prospective Register of Systematic Reviews under the registration number CRD420251113749. Eligibility criteria The study inclusion criteria were as follows: (1) randomized controlled trials (RCTs); (2) inclusion of patients aged ≥65 years undergoing elective colonoscopy; (3) comparison of low-volume (≤2 L) PEG-Asc regimens with OS regimens—either OSS or OST; and (4) reporting of at least one prespecified outcome of interest, including bowel preparation efficacy and tolerability outcomes. Studies were excluded if they (1) lacked parallel study arms for both PEG-Asc and OS preparations; (2) combined age groups without providing extractable data for patients aged ≥65 years; (3) involved overlapping or duplicate patient populations; or (4) failed to provide extractable data on any of the prespecified outcomes of interest. No restrictions on the publication date, language, or follow-up duration were applied. Outcomes The primary outcomes were bowel preparation quality measures, including overall bowel cleansing success and total and segmental Boston bowel preparation scale (BBPS) scores. The secondary outcomes included lesion detection (polyp detection rate [PDR] and adenoma detection rate [ADR]), procedural metrics (cecal intubation rate and withdrawal time), patient-reported outcomes (satisfaction based on visual analog scale scores and willingness to reuse the same preparation), and tolerability outcomes (thirst, nausea, vomiting, abdominal pain, and abdominal distention). Given the number of secondary outcomes assessed, the secondary analyses were considered exploratory and interpreted cautiously without formal adjustment for multiple comparisons. Search strategy, study selection, and data extraction The PubMed, Embase, and Cochrane databases were systematically searched from their inception until May 1, 2025. The following search strategy was used: (OSS OR OST OR sulfate OR sulphate) AND (polyethylene glycol OR PEG) AND (bowel preparation OR bowel cleansing OR colonoscopy OR endoscopy). The reference lists of the included studies were reviewed to identify additional eligible studies. Data were extracted for the prespecified primary and secondary outcomes listed above, including successful bowel preparation rates, total and segmental BBPS scores, PDR, ADR, cecal intubation rate, withdrawal time, patient satisfaction (visual analog scale), willingness to reuse the same preparation, and tolerability outcomes (thirst, nausea, vomiting, abdominal pain, and abdominal distention). When both intention-to-treat and per-protocol data were available, the per-protocol data were extracted. Study selection and data extraction were performed independently by A.E.B. and G.T. Disagreements were resolved by consensus among the authors. Quality assessment The risk of bias was independently assessed by A.E.B. and G.T using the Cochrane Risk of Bias 2 (RoB 2) tool.18 Disagreements were resolved by consensus. Publication bias was not formally assessed because fewer than ten studies were included, and such assessments were considered unreliable. Statistical analysis Dichotomous outcomes were compared using pooled risk ratios (RRs) with 95% confidence intervals (CIs), and continuous outcomes were compared using mean differences (MDs) with 95% CIs. Heterogeneity was evaluated using Cochran’s Q and I2 tests. For Cochran’s Q test, p<0.10 indicated significant heterogeneity. For I2 statistics, heterogeneity was categorized as low (≤25%), moderate (26%–50%), substantial (51%–75%), or considerable (>75%). The DerSimonian and Laird19 random-effects model was used for all outcomes. Sensitivity analyses were performed using the Hartung-Knapp-Sidik–Jonkman (HKSJ) approach for outcomes that were statistically significant in the primary analysis, given the small number of included studies. All statistical analyses were performed using Review Manager ver. 5.4 (Nordic Cochrane Center, The Cochrane Collaboration). RESULTS Study selection and baseline characteristics An initial search using the aforementioned strategy yielded 1,463 studies (Fig. 1). After excluding duplicate reports and studies that did not meet the eligibility criteria based on titles or abstracts, 41 studies remained for full-text review. Consequently, six studies were included in the meta-analysis.20-25 Of these, three studies20,22,23 focused on the geriatric population, whereas the other three21,24,25 provided data on the general adult population. However, since patient-level data for those aged ≥65 years could be extracted, these studies21,24 were also included in the analysis. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study screening and selection. OS, oral sulfate; PEG-Asc, polyethylene glycol-ascorbate. The general characteristics of the included studies are presented in Tables 1 and 2.20-25 A total of 707 patients were enrolled in this study. After accounting for withdrawals and dropouts, the bowel preparation outcomes were evaluated in 682 patients: 340 and 342 in the OS and PEG-Asc groups, respectively. In the majority of patients (87.9%), the indication for colonoscopy was either screening or surveillance. In four studies,21,23-25 OST was used as the OS regimen, whereas OSS was used in the remaining two.20,22 In the PEG-Asc group, four studies20,21,23,24 used a 2-L split-dose regimen, whereas the other two used a 1-L split-dose regimen.22,25 In all studies, dietary restrictions, either a low-fiber or low-residue diet, were started 3 days prior to colonoscopy. Table 1.Patient characteristics and colonoscopy indicationsCharacteristicNam et al.20 (2022)Kim et al.21 (2022)Lim et al.22 (2023)Kang et al.23 (2024)Jung et al.24 (2024)Park et al.25 (2024)Participants Total patients189611062544453 Per-protocol189611042314453 Male116 (61.4)NR (44.1)a)61 (57.5)133 (52.4)NR (53.6)a)NR (55.7)a) Age (yr)71.48±4.1465–83 (≥70, 20/61)70.5±4.974.6±3.768.8±3.2NR BMI (kg/m²)NR23.65±2.95a)24.0±3.624.2±3.019–3024.62±3.20a)Indication for colonoscopy Screening/surveillance154 (81.5)61 (100.0)106 (100.0)188 (74.0)44 (100.0)NR (89.1)a) Screening61 (32.3)NR (67.0)a)NRNRNR (55.0)a)NR Surveillance93 (49.2)NR (33.0)a)NRNRNR (45.0)a)NR Diagnostic/symptomatic35 (18.5)0 (0)0 (0)66 (26.0)0 (0)NR (10.9)a)Values are presented as number only, number (%), or mean±standard deviation. Kim reported age as a range, with the number of participants aged ≥70 years, and Jung reported BMI as a range.NR, not reported; BMI, body mass index.a)Values are reported for the overall study population and not separately for the subgroup aged ≥65 years. Patient characteristics and colonoscopy indications Values are presented as number only, number (%), or mean±standard deviation. Kim reported age as a range, with the number of participants aged ≥70 years, and Jung reported BMI as a range. NR, not reported; BMI, body mass index. Values are reported for the overall study population and not separately for the subgroup aged ≥65 years. Table 2.Bowel preparation protocols in included studiesVariableNam et al.20 (2022)Kim et al.21 (2022)Lim et al.22 (2023)Kang et al.23 (2024)Jung et al.24 (2024)Park et al.25 (2024)PEG-Asc RegimenSplit-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM/AM+PM) Purgative volume per dose (mL)1,0001,0005001,0001,000500 Additional water per dose (mL)500Not reported500500500500 AdjunctsNoneNoneNoneNoneNoneNoneOS ProductOSSOSTOSSOSTOSTOST RegimenSplit-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM)Split-dose (PM+AM/AM+PM) Purgative amount per dose (mL)177 OSS (473 with water)14 Tablets177 OSS (473 with water)14 Tablets14 Tablets14 Tablets Additional water per dose (mL)9461,0004731,0008501,275 AdjunctsNoneSimethiconeNoneSimethiconeSimethiconeSimethicone Diet restriction before colonoscopyLow-fiber×3 daysLow-fiber×3 daysLow-fiber×3 daysLow-residue×3 daysLow-residue×3 daysLow-fiber×3 days Procedure timingMorningMorningMorningMorningMorningMorning/AfternoonPEG-Asc, polyethylene glycol-ascorbate; OS, oral sulfate-based; OSS, oral sulfate solution; OST, oral sulfate tablets. Bowel preparation protocols in included studies PEG-Asc, polyethylene glycol-ascorbate; OS, oral sulfate-based; OSS, oral sulfate solution; OST, oral sulfate tablets. A consolidated summary of all outcomes is provided in Table 3, and detailed estimates are presented in the following sections. Bowel preparation quality outcomes were considered primary outcomes, and all other outcomes were analyzed as secondary. Table 3.Summary of pooled effect measures for all outcomesSectionOutcomeNo. of studiesn (OS/PEG-Asc)a) or events/n (OS vs. PEG-Asc)b)Effect size (95% CI)p-valueI² (%)Continuous outcomesTotal BBPS5318/311MD 0.08 (–0.10 to 0.27)0.362Right colon BBPS3239/242MD 0.21 (–0.01 to 0.42)0.0670Transverse colon BBPS3239/242MD 0.10 (–0.04 to 0.25)0.1658Left colon BBPS3239/242MD 0.11 (–0.04 to 0.25)0.1548Withdrawal time (seconds)3263/262MD 28.42 (–37.67 to 94.51)0.400Overall satisfaction (VAS)5313/325MD 0.69 (0.10–1.29)0.0270Dichotomous outcomesOverall bowel cleansing success4269/289 vs. 266/279RR 0.99 (0.95–1.03)0.7019Perfect segment score (BBPS=3), right colon3138/237 vs. 95/227RR 1.31 (0.98–1.75)0.0757Perfect segment score (BBPS=3), transverse colon3168/237 vs. 139/227RR 1.15 (0.97–1.38)0.1134Perfect segment score (BBPS=3), left colon3165/237 vs. 139/227RR 1.11 (0.93–1.31)0.2536Polyp detection rate3162/239 vs. 134/242RR 1.21 (1.01–1.45)0.0435Adenoma detection rate4177/291 vs. 137/294RR 1.28 (1.10–1.49)0.0010Cecal intubation rate3260/262 vs. 261/262RR 1.00 (0.98–1.01)0.850Complete consumption of preparation4196/198 vs. 226/229RR 1.01 (0.98–1.03)0.650Willingness to reuse the same preparation5258/311 vs. 233/310RR 1.09 (0.97–1.23)0.1548Thirst326/174 vs. 24/163RR 0.49 (0.07–3.20)0.4683Nausea661/340 vs. 57/342RR 1.08 (0.77–1.50)0.660Vomiting621/340 vs. 12/342RR 1.61 (0.70–3.69)0.2612Abdominal distention438/198 vs. 46/209RR 0.91 (0.43–1.95)0.8146Abdominal pain622/340 vs. 26/342RR 0.82 (0.27–2.51)0.7345For continuous outcomes, values represent the number of participants analyzed per arm. For dichotomous outcomes, values represent events/participants per arm. Overall bowel cleansing success was defined as all segments with BBPS ≥2 and a total BBPS ≥6.OS, oral sulfate-based; PEG-Asc, polyethylene glycol-ascorbate; CI, confidence interval; BBPS, Boston bowel preparation scale; MD, mean difference; VAS, visual analog scale; RR, risk ratio.a)For continuous outcomes, values represent the number of participants analyzed per arm (OS/PEG-Asc). b)For dichotomous outcomes, values represent events/total participants per arm (OS vs. PEG-Asc). Summary of pooled effect measures for all outcomes For continuous outcomes, values represent the number of participants analyzed per arm. For dichotomous outcomes, values represent events/participants per arm. Overall bowel cleansing success was defined as all segments with BBPS ≥2 and a total BBPS ≥6. OS, oral sulfate-based; PEG-Asc, polyethylene glycol-ascorbate; CI, confidence interval; BBPS, Boston bowel preparation scale; MD, mean difference; VAS, visual analog scale; RR, risk ratio. a)For continuous outcomes, values represent the number of participants analyzed per arm (OS/PEG-Asc). b)For dichotomous outcomes, values represent events/total participants per arm (OS vs. PEG-Asc). Bowel cleansing outcomes A bowel preparation was deemed successful when all colonic segments had a BBPS score ≥2 and a cumulative score ≥6. Successful preparation was achieved in 289 of 311 patients receiving OS (92.9%) and in 293 of 310 patients receiving PEG-Asc (94.5%), yielding no significant difference between the two groups (RR, 1.00; 95% CI, 0.96–1.03; p=0.81; I2=0%; Fig. 2). Pooled data of total BBPS scores echoed this finding (MD, 0.08; 95% CI, −0.10 to 0.27; p=0.36; I2=2 %; Fig. 3). Segmental BBPS scores likewise showed no statistically significant advantage for either regimen in the right colon (MD, 0.21; 95% CI, −0.01 to 0.42; p=0.06; I2=70%), transverse colon (MD, 0.10; 95% CI, −0.04 to 0.25; p=0.16; I2=58%), or left colon (MD, 0.11; 95% CI −0.04 to 0.25; p=0.15; I2=48%). Forest plot of studies comparing overall bowel cleansing success in oral sulfate (OS)-based vs. low-volume polyethylene glycol-ascorbate (PEG-Asc) regimens. M-H, Mantel-Haenszel method; CI, confidence interval; DL, DerSimonian-Laird. Forest plot of studies comparing total Boston bowel preparation scale (BBPS) score in oral sulfate (OS)-based and low-volume polyethylene glycol-ascorbate (PEG-Asc) regimens. SD, standard deviation; IV, intravenous; CI, confidence interval; DL, DerSimonian-Laird. Perfect preparation was defined as a BBPS score of 3 in all three colonic segments, with a total BBPS score of 9. A pooled analysis of the overall perfect preparation could not be performed because these data were available only from the studies by Lim and Kang. In Kang’s study, perfect preparation was significantly more frequent with OS than with PEG‑Asc (55.7% vs. 28.4%, p<0.001). Lim showed the same directional trend, although the difference between OS and PEG‑Asc in perfect preparation was not statistically significant (30.8% vs. 17.3%, p=0.17). When the rates of perfect segmental preparations were pooled across studies, OS consistently yielded higher rates in every colonic segment, although none of these comparisons achieved statistical significance (right colon: RR, 1.31; 95% CI, 0.98–1.75; p=0.07; I2=57%; transverse colon: RR, 1.15; 95% CI, 0.97–1.38; p=0.11; I2=34%; and left colon: RR, 1.11, 95% CI, 0.93–1.31; p=0.25; I2=36%). Procedural metrics In the secondary analyses, OS was associated with higher lesion detection compared with PEG-Asc. Polyps were detected in 162 of 239 patients in the OS group (67.8%) and in 134 of 242 patients in the PEG-Asc group (55.4%). This translates to a 21% relative increase in PDR with OS (RR, 1.21; 95% CI, 1.01–1.45; p=0.04; I2=35%; Fig. 4A). The difference in ADR also favored OS (177 of 291 patients, 60.8%) compared with PEG-Asc (137 of 294 patients, 46.6%), indicating a 28% higher detection rate (RR, 1.28; 95% CI, 1.10–1.49; p=0.001; I2=0%; Fig. 4B). The number needed to treat (NNT) with OS instead of PEG-Asc to detect one additional polyp or adenoma was 8 and 7, respectively. Forest plot of studies comparing lesion detection between oral sulfate (OS)-based and low-volume polyethylene glycol-ascorbate (PEG-Asc) regimens: (A) polyp detection rate and (B) adenoma detection rate. M-H, Mantel-Haenszel method; CI, confidence interval; DL, DerSimonian-Laird. Cecal intubation rate exceeded 99% in both groups, occurring in 260 of 262 patients in the OS group and in 261 of 262 patients in the PEG-Asc group (RR, 1.00; 95% CI, 0.98–1.01; p=0.85; I2=0 %). In terms of colonoscopy procedural times, we were only able to perform a pooled analysis for withdrawal time owing to the lack of available data for other parameters, which did not significantly differ between the two groups (MD, 28.42 seconds; 95% CI, −37.67–94.51; p=0.40; I2=0%). Patient-centered outcomes Nearly all patients completed the prescribed bowel preparations in the four studies that reported this outcome (OS, 98.9% vs. PEG-Asc, 98.5%; RR, 1.01; 95% CI, 0.98–1.03; p=0.63; I2=0%). In Kang’s study, the full-consumption rates were not specified; however, every participant consumed at least 75% of their assigned preparation. In Jung’s study, all patients in the OS group finished the entire preparation, and 98.1% did so in the PEG-Asc group, with no age-specific data available for the subgroup aged ≥65 years. Overall satisfaction was assessed using a 10‑point visual analog scale (1=worst; 10=best). OS users rated their experience 0.7 points higher on average (MD, 0.69; 95% CI, 0.10–1.29; p=0.02; I2=70%). However, no significant difference in willingness to reuse the same regimen at a future colonoscopy was observed between the two groups (OS, 83.0% vs. PEG-Asc, 75.2%; RR, 1.09; 95% CI, 0.97–1.23; p=0.15; I2=48%). Adverse‑event profiles were comparable between regimens, with no statistically significant differences in any reported symptom, including thirst (RR, 0.49; 95% CI, 0.07–3.20; p=0.46; I2=83%), nausea (RR, 1.08; 95% CI, 0.77–1.50; p=0.66; I2=0%), vomiting (RR, 1.61; 95% CI, 0.70–3.69; p=0.26; I2=12%), abdominal distention (RR, 0.91; 95% CI, 0.43–1.95; p=0.81; I2=46%), and abdominal pain (RR, 0.82; 95% CI, 0.27–2.51; p=0.73; I2=45%). Electrolyte disturbances None of the included trials reported clinically meaningful electrolyte changes when assessed individually. Therefore, pooled analysis was not performed. Subgroup analyses Three prespecified subgroup analyses were performed: (1) OST versus PEG-Asc, (2) OS versus the 2-L PEG-Asc regimen, and (3) trials specifically designed for a population aged ≥65 years from the outset. The detailed results are presented in Supplementary Tables 1–3. Relative to the primary analysis, only two outcomes were statistically significant: participants in the OST subgroup were more willing to reuse the same preparation (RR, 1.22; p<0.01), whereas the OS-related advantage in overall satisfaction disappeared in both the 2-L PEG-Asc subgroup (MD, 0.85; p=0.11) and geriatric-specific trials (MD, 0.50; p=0.14). All the other endpoints were directionally and statistically consistent with the main findings. Sensitivity analyses In the sensitivity analyses using the HKSJ method, the association between OS and higher ADR remained statistically significant (RR, 1.28; 95% CI, 1.02–1.61; p=0.04; I2=0%). By contrast, the pooled effects for PDR (RR, 1.21; 95% CI, 0.85–1.72; p=0.15; I2=35%) and overall satisfaction (MD, 0.69; 95% CI, −0.19 to 1.58; p=0.09; I2=70%) were attenuated and no longer statistically significant, although effect estimates remained directionally consistent with the primary analysis. Quality assessment The risk of bias was assessed for each study using the Cochrane RoB 2 tool.18 Five studies were judged to be at low risk across all domains; Park showed some concerns due to an imbalance in post-randomization withdrawals between study arms (Supplementary Fig. 1). DISCUSSION This systematic review and meta-analysis of six RCTs compared the efficacy and tolerability of low-volume PEG-Asc and OS bowel preparation regimens in patients aged ≥65 years. Both regimens achieved comparable bowel cleansing quality, as reflected by successful bowel preparation rates and total and segmental BBPS scores. Despite this similarity, secondary analyses suggested higher lesion detection with OS and higher PDR (RR, 1.21; NNT, 8) and ADR (RR, 1.28; NNT, 7). Patient-reported satisfaction modestly favored OS, whereas willingness to reuse the regimen and full-dose completion rates were similar between the groups. The patient-reported adverse events and procedural efficiencies were comparable. Sensitivity analyses using the HKSJ approach showed that the association with ADR remained statistically significant, whereas the effects on PDR and overall satisfaction were no longer statistically significant. Earlier meta‑analyses comparing OS with standard or low‑volume PEG preparations across mixed‑age cohorts also concluded that cleansing efficacy and general tolerability are non‑inferior with OS regimens.9,26 However, these studies did not focus on older adults—a population with distinct physiological and practical challenges such as slower gut transit, polypharmacy, intolerance to large volumes, and cognitive or physical limitations.3,10,11 Our findings extend the evidence base by showing that the efficacy-safety balance of OS versus PEG‑Asc persists in the geriatric setting and that OS was associated with higher lesion detection, even when commonly reported cleansing metrics appeared similar. Although the overall cleansing success and mean BBPS scores were comparable between the groups, OS was associated with higher ADR and PDR, consistent with prior evidence showing higher detection with OS compared to PEG-based regimens.8,9,27-29 In conservative HKSJ sensitivity analyses, the ADR association persisted, whereas the PDR association was attenuated and no longer statistically significant. One possible explanation is that commonly used definitions of adequate or successful bowel preparation (total BBPS ≥6 with all segments ≥2) may not capture subtler but clinically relevant differences in mucosal visualization—such as residual turbid fluid, thin stool film, or adherent mucus—that can persist despite a preparation being classified as successful. These residual factors may affect the detection of subtle lesions and may be more significant in older adults with a higher baseline prevalence of colorectal neoplasia. Supporting this possibility, a meta-analysis has reported similar rates of adequate preparation between OS and PEG-Asc (RR, 1.02; p=0.16) but higher rates of perfect preparation (BBPS=9) with OS (RR, 1.18; p=0.03) in adults.9 In our meta-analysis, the two studies reporting overall perfect preparation both favored OS; Kang’s study23 showed significantly better rates, whereas Lim’s study22 showed a similar directional trend but was underpowered. Pooled analyses of perfect segmental scores also consistently favored OS, although the differences were not statistically significant, likely because of limited power. Collectively, these signal-consistent findings suggest that OS may achieve optimal segmental cleansing in some patients, which could contribute to better lesion detection by improving mucosal exposure. Nonetheless, lesion detection is multifactorial. In a post hoc RCT analysis, detection improved when BBPS was ≥6 compared with <6, but did not differ significantly between BBPS 9 and 7–8; withdrawal time and preparation compliance were independent determinants of ADR.30 Therefore, although more optimal segmental cleansing with OS may plausibly contribute to higher detection, this study-level meta-analysis cannot establish causality, and larger, geographically diverse studies powered for lesion detection as a primary endpoint and adjusted for determinants of lesion detection (e.g., withdrawal time, colonoscopy indication, endoscopist performance, and center effects), are needed to confirm these findings and determine whether any detection advantage translates into improved long-term outcomes, such as reduced post-colonoscopy CRC risk. Although a previous meta-analysis has reported that OSS was more frequently associated with nausea and vomiting than PEG-Asc, our study did not observe such differences in the geriatric population.9 In fact, no significant differences were observed in any of the pooled patient-reported adverse events. Overall satisfaction showed a small directional difference favoring OS in the primary analysis; however, substantial heterogeneity was present, and the difference was not statistically significant in the HKSJ sensitivity analyses. Accordingly, satisfaction should be interpreted with caution. To the best of our knowledge, this meta-analysis is the first to investigate the efficacy and tolerability of OS compared to PEG-Asc in a geriatric population with specific age-related dynamics. We also provided clinically actionable evidence for low-volume bowel preparation in the geriatric population. However, this study has some limitations. First, it included a relatively small number of studies, and all were conducted in Korean centers, which limited the precision of the pooled estimates and the strength of inference, particularly for secondary outcomes. Accordingly, these findings should be interpreted with caution and confirmed in larger, geographically diverse studies. In addition, differences in population characteristics such as dietary patterns, baseline bowel habits, and comorbidity profiles may influence bowel-cleansing efficacy and tolerability; therefore, external validation in western populations of different ethnic backgrounds is warranted. Second, the bowel preparation regimens were not identical between the two groups; some studies used sulfate tablets, whereas others used different solutions and volumes, which could explain some of the differences and heterogeneity we observed. Third, we were unable to adjust for important determinants of lesion detection, including withdrawal time, indication for colonoscopy, endoscopist performance, and center effects. Consequently, the findings related to ADR and PDR should be interpreted as associations rather than causal effects. Meta-regression analysis was not performed because fewer than ten studies were available, and key covariates were inconsistently reported across studies, rendering such analyses statistically unreliable. Fourth, although the PDR and ADR were reported, data on the total number of polyps or adenomas detected per colonoscopy were not provided. Consequently, we were unable to assess the lesion burden or compare the mean number of lesions between groups. Fifth, most included studies excluded individuals with severe constipation, advanced renal impairment, or significant cardiac comorbidities (Supplementary Table 4),20-25 which may limit the generalizability of our findings to a broader geriatric population. Finally, we did not perform a pooled analysis of changes in electrolyte or serum creatinine levels because the clinical and statistical significance of these parameters often differ substantially. Combining such data across studies can lead to misleading interpretations of results. Nonetheless, findings from individual studies suggest that both preparations are safe in terms of electrolyte disturbances and renal function. Despite these limitations, our results have pragmatic implications. Guidelines from the US Multi‑Society Task Force and other societies recognize both PEG‑Asc and OS as acceptable low‑volume alternatives for routine practice, yet provide little age‑specific guidance.3,14,15 Therefore, OS can be considered an appropriate low-volume option for adults aged ≥65 years when selecting a bowel preparation, alongside PEG-Asc, with choice individualized based on comorbidities, tolerability, and patient preference. Whether OS confers a true lesion-detection advantage beyond adequate cleansing warrants confirmation in larger trials. In this meta-analysis of RCTs in adults aged ≥65 years, OS and PEG-Asc regimens demonstrated comparable bowel cleansing quality, tolerability, and patient-reported adverse event profiles. A signal toward higher lesion detection was observed for OS in the primary analysis, and the association with adenoma detection remained statistically significant in the conservative sensitivity analyses. Larger, geographically diverse studies powered by lesion detection outcomes are needed to confirm whether these findings translate into meaningful long-term clinical benefits. Footnotes Ethical Statements Not applicable. Conflicts of Interest The authors have no potential conflicts of interest. Funding None. Author Contributions Conceptualization: AEB, GT; Data curation: AEB, GT, YY, ZI; Formal analysis: AEB, GT; Methodology: AEB, GT, SM; Software: AEB, AIB; Supervision: SK; Visualization: AEB, AIB; Writing–original draft: AEB, GT; Writing–review & editing: all authors. Supplementary Material Supplementary Table 1. Subgroup meta-analysis: oral sulfate tablets vs. PEG-Asc. Supplementary Table 2. Subgroup meta-analysis: all OS regimens vs. 2-L PEG-Asc. Supplementary Table 3. Subgroup meta-analysis restricted to trials specifically designed for adults ≥65 years. Supplementary Table 4. Exclusion and eligibility criteria by study. Supplementary Fig. 1. Risk of bias assessment using the Cochrane RoB 2 tool.18 Each study (rows) was evaluated across five domains (columns). Assessment showed some concerns for the Park study due to an imbalance in post-randomization withdrawals between study arms while other studies were judged low risk across all domains. Supplementary materials related to this article can be found online at https://doi.org/10.5946/ce.2025.430. REFERENCES Associated Data Supplementary Materials Supplementary Table 1. Subgroup meta-analysis: oral sulfate tablets vs. PEG-Asc. Supplementary Table 2. Subgroup meta-analysis: all OS regimens vs. 2-L PEG-Asc. Supplementary Table 3. Subgroup meta-analysis restricted to trials specifically designed for adults ≥65 years. Supplementary Table 4. Exclusion and eligibility criteria by study. Supplementary Fig. 1. Risk of bias assessment using the Cochrane RoB 2 tool.18 Each study (rows) was evaluated across five domains (columns). Assessment showed some concerns for the Park study due to an imbalance in post-randomization withdrawals between study arms while other studies were judged low risk across all domains.